Abstract
Adenocarcinoma of the pancreas is the fourth leading cause of cancer-related death in the United States. Therapeutic responsiveness of pancreatic cancer to surgery, chemotherapy, and radiation therapy is poor, resulting in a dismal 5-year survival of less than 3%. Point mutation of the K-ras oncogene is a common event in the early development of pancreatic cancer. Indeed, K-ras mutations occur in up to 95% of pancreatic cancers, with a resulting overall increase in production of reactive oxygen species (ROS) through the activation of NADPH oxidase (NOX). Specifically, the extracellular (non-mitochondrial) generation of superoxide (O2.-) from the NOX system results in cell growth and tumor progression. Extracellular superoxide dismutase (SOD3, EcSOD) is the only isoform of superoxide dismutase (SOD) expressed extracellularly. It modulates ROS by converting O2.- into hydrogen peroxide (H2O2). Antioxidant enzymes that scavenge specific ROS have inhibited the in vitro and in vivo growth of pancreatic cancer. It has been demonstrated that overexpression of EcSOD inhibits pancreatic cancer cell growth and intracellular signaling pathways. Therefore, we propose that strategies to scavenge non-mitochondrial-generated superoxide may prove beneficial in the treatment pancreatic cancer. This review will focus on the role of O2.- as a pro-tumorigenic signaling molecule, including its generation and hypothesized mechanism of action, as well as the role of EcSOD in inhibiting tumor growth and propagation, and its potential as a targeted pancreatic cancer therapy.
Keywords: Superoxide, pancreatic cancer, superoxide dismutase, hypoxia-inducible factor-1α.
Current Cancer Therapy Reviews
Title:Extracellular Superoxide and the Growth of Pancreatic Carcinoma
Volume: 9 Issue: 4
Author(s): John A. Cieslak and Joseph J. Cullen
Affiliation:
Keywords: Superoxide, pancreatic cancer, superoxide dismutase, hypoxia-inducible factor-1α.
Abstract: Adenocarcinoma of the pancreas is the fourth leading cause of cancer-related death in the United States. Therapeutic responsiveness of pancreatic cancer to surgery, chemotherapy, and radiation therapy is poor, resulting in a dismal 5-year survival of less than 3%. Point mutation of the K-ras oncogene is a common event in the early development of pancreatic cancer. Indeed, K-ras mutations occur in up to 95% of pancreatic cancers, with a resulting overall increase in production of reactive oxygen species (ROS) through the activation of NADPH oxidase (NOX). Specifically, the extracellular (non-mitochondrial) generation of superoxide (O2.-) from the NOX system results in cell growth and tumor progression. Extracellular superoxide dismutase (SOD3, EcSOD) is the only isoform of superoxide dismutase (SOD) expressed extracellularly. It modulates ROS by converting O2.- into hydrogen peroxide (H2O2). Antioxidant enzymes that scavenge specific ROS have inhibited the in vitro and in vivo growth of pancreatic cancer. It has been demonstrated that overexpression of EcSOD inhibits pancreatic cancer cell growth and intracellular signaling pathways. Therefore, we propose that strategies to scavenge non-mitochondrial-generated superoxide may prove beneficial in the treatment pancreatic cancer. This review will focus on the role of O2.- as a pro-tumorigenic signaling molecule, including its generation and hypothesized mechanism of action, as well as the role of EcSOD in inhibiting tumor growth and propagation, and its potential as a targeted pancreatic cancer therapy.
Export Options
About this article
Cite this article as:
A. Cieslak John and J. Cullen Joseph, Extracellular Superoxide and the Growth of Pancreatic Carcinoma, Current Cancer Therapy Reviews 2013; 9 (4) . https://dx.doi.org/10.2174/157339470904140418095056
DOI https://dx.doi.org/10.2174/157339470904140418095056 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue "Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics" aims to explore cutting-edge developments and innovative strategies in the field of lipid nanoparticle (LNP) technology, particularly focusing on its application in mRNA delivery. This topic has gained unprecedented attention and urgency in the wake of the COVID-19 ...read more
Current Progress in Protein Degradation and Cancer Therapy
Targeted Protein Degradation is gaining momentum in cancer therapy; it facilitates targeting undruggable proteins, overcomes cancer resistance, and avoids undesirable side effects. Thus small molecule degraders have emerged as novel therapeutic strategies. Targeted protein degradation (TPD), the process of eliminating a protein of interest holds a great promise for the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma on Cirrhosis: State of the Art and Future Perspectives
Recent Patents on Anti-Cancer Drug Discovery The Preclinical Bases of the Rational Combination of Paclitaxel and Antiangiogenic Drugs
Clinical Cancer Drugs CIAPIN1 siRNA Inhibits Proliferation, Migration and Promotes Apoptosis of VSMCs by Regulating Bcl-2 and Bax
Current Neurovascular Research Mucosal Immune Regulation and Vaccines for Helicobacter-associated Gastritis
Current Chemical Biology Functionalized magnetic nanoparticles for biomedical applications
Current Pharmaceutical Design CB Receptor Ligands from Plants
Current Topics in Medicinal Chemistry Immune Modulation by Regulatory T Cells in Helicobacter pylori-Associated Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets HOTAIR Competitively Binds MiRNA330 as a Molecular Sponge to Increase the Resistance of Gastric Cancer to Trastuzumab
Current Cancer Drug Targets DNA Copy Number Profiles Correlate with Outcome in Colorectal Cancer Patients Treated with Fluoropyrimidine/Antifolate-based Regimens
Current Drug Metabolism Immunity to Tumour Antigens
Current Pharmaceutical Design Repurposing of Metformin for Cancer Therapy: Updated Patent and Literature Review
Recent Patents on Anti-Cancer Drug Discovery Pleiotropic Effects of Cathepsin D
Endocrine, Metabolic & Immune Disorders - Drug Targets Derivatives and Analogues of Resveratrol: Recent Advances in Structural Modification
Mini-Reviews in Medicinal Chemistry Suppression of Cancer Invasiveness by Dietary Compounds
Mini-Reviews in Medicinal Chemistry Marine Collagen as a Source of Bioactive Molecules: A Review
The Natural Products Journal Chemotherapy in Addition to Preoperative Radiotherapy in Locally Advanced Rectal Cancer – A Systematic Overview
Reviews on Recent Clinical Trials Diagnosis and Treatment of Alzheimers Disease
Current Medicinal Chemistry - Central Nervous System Agents Gender Differences in P-Glycoprotein Expression and Function: Effects on Drug Disposition and Outcome
Current Drug Metabolism Black Tea Polyphenols-Mediated In Vivo Cellular Responses During Carcinogenesis
Mini-Reviews in Medicinal Chemistry Nuclear Imaging of Prostate Cancer with Gastrin-Releasing-Peptide- Receptor Targeted Radiopharmaceuticals
Current Pharmaceutical Design